161 EXPRESSION OF HUMAN EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1 (HENT1) IS A NOVEL PROGNOSIC MARKER IN ADVANCED BLADDER CANCER PATIENTS WITH GEMCITABINE-BASED CHEMOTHERAPY

Abstract

You have accessJournal of UrologyUrothelial Cancer: Natural History & Pathophysiology/Markers1 Apr 2010161 EXPRESSION OF HUMAN EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1 (HENT1) IS A NOVEL PROGNOSIC MARKER IN ADVANCED BLADDER CANCER PATIENTS WITH GEMCITABINE-BASED CHEMOTHERAPY Nagahide Matsumura, Yasushi Nakamura, Yoshihito Nanpo, Yumiko Sasaki, Yoshiki Kodama, Leona Fujii, Takeshi Inagaki, Yasuo Kohjimoto, and Isao Hara Nagahide MatsumuraNagahide Matsumura More articles by this author , Yasushi NakamuraYasushi Nakamura More articles by this author , Yoshihito NanpoYoshihito Nanpo More articles by this author , Yumiko SasakiYumiko Sasaki More articles by this author , Yoshiki KodamaYoshiki Kodama More articles by this author , Leona FujiiLeona Fujii More articles by this author , Takeshi InagakiTakeshi Inagaki More articles by this author , Yasuo KohjimotoYasuo Kohjimoto More articles by this author , and Isao HaraIsao Hara More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2010.02.215AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Gemcitabine, a cytotoxic pyrimidine deoxynucleoside analogue, is transported into the cell mostly by human equilibrative nucleoside transporters (hENT). In the present study, we studied whether the expression level of hENT1 can predict survival in advanced bladder cancer treated by gemcitabine-based chemotherapy. METHODS Clinical data were retrieved from the databases from May 2002 to July 2009 in 40 patients (age35-88; male 36 female 4) with advanced bladder cancer treated by GC (Gemcitabine+Cisplatin) regimen (17 patients) and GCT (GC+Paclitaxel) regimen (23 patients). Inclusion criteria for this trial were clinically and/or histologically documented advanced and/or metastatic (stage 4) bladder cancer. We studied the expression level of hENT1 by immunohistochemical staining formalin-fixed, paraffin-embedded bladder cancer tissues of these 40 patients with the hENT1 specific polyclonal antibody. Pathologist blinded to clinical outcomes evaluated expression level of hENT1 by intensity(0□ ‘3+) and percentage of staining. The clinical and histopathological data were analyzed to evaluate predictive factors. RESULTS Of the 40 tissue samples, 20 samples revealed hENT1 high expression (intensity score 3+ with uniformly [>50%] detectable hENT1 staining) and 20 samples revealed hENT1 low expression. Patients with hENT1 low expression had a median overall survival of 11.6months from initiation of gemcitabine chemotherapy. In contrast, patients with hENT1 high expression had a median survival of 17.3 months. Kaplan-Meier analysis of survival from gemcitabine initiation revealed a significant separation in the survival curves (Fig. p=0.0026). Moreover, only hENT1 expression turned out to be an independent prognostic factor (p=0.003) by multivariate analysis. CONCLUSIONS Patients with bladder cancer expressing high level of hENT1 showed significantly better overall survival than did patients with bladder cancer expressing low level of hENT1. Immunohistochemical evaluation of hENT1 expression can be a promising biomarker which can predict the clinical response and the prognosis of patients with advanced bladder cancer treated by gemcitabine-based chemotherapy. Wakayama, Japan© 2010 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 183Issue 4SApril 2010Page: e65-e66 Advertisement Copyright & Permissions© 2010 by American Urological Association Education and Research, Inc.MetricsAuthor Information Nagahide Matsumura More articles by this author Yasushi Nakamura More articles by this author Yoshihito Nanpo More articles by this author Yumiko Sasaki More articles by this author Yoshiki Kodama More articles by this author Leona Fujii More articles by this author Takeshi Inagaki More articles by this author Yasuo Kohjimoto More articles by this author Isao Hara More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...